<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466128</url>
  </required_header>
  <id_info>
    <org_study_id>06U.528</org_study_id>
    <nct_id>NCT00466128</nct_id>
  </id_info>
  <brief_title>Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)</brief_title>
  <official_title>A Double-blinded Randomized Controlled Trial With Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Between 24 and 32 Weeks Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the short term use of indomethacin will reduce&#xD;
      the number of women delivering within 48 hours when given to women with preterm premature&#xD;
      rupture of membranes (PPROM) between 24- 32 weeks of gestation. We hypothesize that&#xD;
      indomethacin's anti-inflammatory and tocolytic action will reduce the number of women&#xD;
      delivering within 48 hours when given to women with PPROM between 24-32 weeks of gestation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm premature rupture of membranes (PPROM) is defined as rupture of the chorioamniotic&#xD;
      membranes before the onset of labor prior to 37 weeks of gestation. The etiology of PPROM is&#xD;
      not well understood but likely to be multifactorial. Although the underlying mechanism of&#xD;
      PPROM is unknown, some speculate it is the human's inflammatory response to bacterial&#xD;
      infection with the subsequent production of prostaglandins which weaken the fetal membranes.&#xD;
      Therefore, the use of indomethacin, a prostaglandin inhibitor, may decrease prostaglandin&#xD;
      synthesis leading to less uterine irritability and prevention of weakened membranes.&#xD;
&#xD;
      This is a double blind randomized controlled trial comparing indomethacin to placebo in women&#xD;
      with PPROM between the gestational ages of 24-32 weeks. Women between the gestational age of&#xD;
      24 to 32 weeks with premature rupture of membranes and not in active labor will be eligible&#xD;
      for this clinical trial. After informed consent, patients will be randomized to either&#xD;
      indomethacin or placebo. Maternal and neonatal outcomes will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolongation of pregnancy (interval from time of randomization to time of delivery) for 48 hours</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolongation of pregnancy for 7 days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Morbidities: birth weight, APGAR scores, sepsis, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), NICU hospitalization days, patent ductus arteriosus (PDA)</measure>
    <time_frame>from admission/birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes: chorioamnionitis, endometritis, labor induction, placental abruption, cesarean section</measure>
    <time_frame>from admission</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Preterm Premature Rupture of Membranes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indomethacin</intervention_name>
    <description>Indomethacin 50mg PO followed by 25mg PO q6hrs</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age between 24 0/7 - 31 5/7 weeks by LMP or ultrasound&#xD;
&#xD;
          -  Documentation of rupture by demonstrating pooling or 2/3 diagnostic tests (pooling,&#xD;
             ferning and nitrazine positivity)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Membrane rupture greater than 72 hours&#xD;
&#xD;
          -  Persistent labor characterized by regular painful contractions with cervical change&#xD;
             and/or cervix visually greater than 5 cm&#xD;
&#xD;
          -  Chorioamnionitis defined by having 2 or more of the following: maternal temperature &gt;&#xD;
             100.4, persistent fetal tachycardia (&gt;170bpm), maternal tachycardia (&gt;110bpm) in the&#xD;
             absence of other likely cause, uterine tenderness.&#xD;
&#xD;
          -  Non-reassuring fetal heart rate tracing or biophysical testing&#xD;
&#xD;
          -  Vaginal hemorrhage&#xD;
&#xD;
          -  Lethal fetal anomalies&#xD;
&#xD;
          -  Intrauterine fetal demise&#xD;
&#xD;
          -  Maternal conditions which precludes expectant management&#xD;
&#xD;
          -  Fetal condition which precludes expectant management&#xD;
&#xD;
          -  Maternal allergy to indomethacin&#xD;
&#xD;
          -  Maternal active gastritis&#xD;
&#xD;
          -  Multiple gestations&#xD;
&#xD;
          -  HIV with viral load &gt;1000&#xD;
&#xD;
          -  HSV with active herpetic lesions&#xD;
&#xD;
          -  Cervical cerclage&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolene S Seibel-Seamon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jolene S Seibel-Seamon, MD</last_name>
    <phone>215-955-9239</phone>
    <email>joleneseibel@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Baxter, MD, MSCP</last_name>
    <phone>215-955-9238</phone>
    <email>jkb105@jefferson.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolene S Seibel-Seamon, MD</last_name>
      <phone>215-955-6293</phone>
      <email>joleneseibel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jolene S Seibel-Seamon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fetal membranes, preterm rupture</keyword>
  <keyword>preterm rupture</keyword>
  <keyword>PPROM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

